× Business
TelecomHealthcareDigital MarketingERPRetailMedia and EntertainmentOil and GasFood and BeveragesMarketing and AdvertisingBanking and InsuranceMetals and MiningLegalComplianceCryptocurrency
Big DataCloudIT ServiceSoftwareMobileSecurityNetworkingStorageCyber SecuritySAPData AnalysisloTBio TechQuality AssuranceEducationE-commerce
Cisco DATABASE Google IBM Juniper Microsoft M2M Oracle Red hat Saas SYMANTEC
CEO ReviewCMO ReviewCFO ReviewCompany Review
Startups Opinion Yearbook Readers Speak Contact Us

Credence Genomics gains popularity in Sri Lankan biotechnology industry

siliconreview Credence Genomics gains popularity in Sri Lankan biotechnology industry

Credence Genomics, the leading NGS based Diagnostics Company based in Colombo, Sri Lanka, has achieved popularity by being the first to be published in the Biomed Central journal. The BMC series is a group of open access, peer reviewed journals that span all areas of biology and medicine. There are over 60 subject-specific journals focused on the needs of individual research communities, offering an efficient, fair and friendly peer review service, and committed to publishing all sound science, provided that there is some advance in knowledge presented by the work. The company is specialized in DNA diagnostic tests and has gained public satisfaction with a fast paced test results system and an uncompromised accuracy level.

Credence is founded by Dr. Vaz Gnanam in 2011 with a team of scientists and ICT engineers to develop leading edge innovative diagnostics tests which have been the result of six years of stringent research on industry defining genetic science, application of information technology and testing across a broad spectrum of diseases. They focus on the NGS technology, which is Next Generation Sequencing. It enables the four basic building blocks found in all life forms to be interpreted as digital data, to be captured, stored in a silicon chip and compared by complex software back-end. This data is further compared with the international standards to determine the data which is being used by many hospitals. The organization has built its own intellectual property and trade secrets in relationship to infectious disease identification and rapid organism detection.